Czechia· CZ-0268188
OPDUALAG
A nivolumab and relatlimab product containing nivolumab + relatlimab, registered in Czechia by Bristol-Myers Squibb Pharma EEIG, Dublin. The same ATC class is registered in 13 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Nivolumab and relatlimab is registered in 13 of 19 countries.
Countries holding a registration under ATC L01FY02 (nivolumab and relatlimab), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 9 of them publish a price we can compare per daily dose
Nivolumab and relatlimab · ATC L01FY02
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- NIVOLUMAB + RELATLIMAB
- Manufacturer
- Bristol-Myers Squibb Pharma EEIG, Dublin
- Country
- Czechia (CZ)
- ATC code
- L01FY02
- ATC class
- Nivolumab and relatlimab
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02681881X20MLCZK 191184.05
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Nivolumab and relatlimab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaOPDUALAGBRISTOL-MYERS SQUIBB CANADA
- SwitzerlandOpdualag (80 mg Relatlimab / 240 mg Nivolumab pro 20 ml), Konzentrat zur Herstellung einer InfusionslösungBristol-Myers Squibb SA
- SpainOPDUALAG 240 MG/80 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONBristol-Myers Squibb Pharma Eeig
- FinlandOpdualagBristol-Myers Squibb Pharma EEIG
- FranceOPDUALAG 240 mg/80 mg, solution à diluer pour perfusionBRISTOL-MYERS SQUIBB / PFIZER EEIG (IRLANDE)
- United KingdomOpdualag 240mg/20ml / 80mg/20ml concentrate for solution for infusion vialsBristol-Myers Squibb Pharmaceuticals Ltd
- IrelandOpdualag 240 mg/80 mg sterile concentrateBristol-Myers Squibb Pharma EEIG
- IcelandOpdualagBristol-Myers Squibb Pharma EEIG*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Opdualag
- Liechtenstein · Opdualag
- Norway · Opdualag
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/399a9a06-6b42-46a9-adc5-ef724cbda6d2 GET /v1/drugs/399a9a06-6b42-46a9-adc5-ef724cbda6d2?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF CNC SOL",
"source": "sukl",
"strength": "240MG/80MG",
"pack_size": "1X20ML",
"substance": "NIVOLUMAB + RELATLIMAB",
"cz_kod_sukl": "0268188",
"product_type": "BT",
"substance_codes": "19818,21975",
"registration_state": "R",
"registration_number": "EU/1/22/1679/001"
}See everything about nivolumab and relatlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.